Abstract 350P
Background
The diagnosis and treatment of breast cancer involves changes in personal, family, social, professional and sexual relationships. In this study we assessed sexual satisfaction in patients with early breast cancer using the validated SEXSAT-Q scale.
Methods
We used the SEXSAT-Q quality of life questionnaire in 60 patients diagnosed with early breast cancer at our centre. Six dimensions were studied: 1. Loss of sexual desire. 2. Alteration of body image. 3. Psychological coping. 4. Discomfort during sexual intercourse. 5. Satisfaction during sexual intercourse. 6. Satisfaction with breast reconstruction. Data were collected in Medical Oncology Department during March 2023.
Results
A sample of 60 patients was selected, aged 26-72 years old, with a median age of 52 years, who had undergone breast cancer surgery, 73.33% by conservative surgery. 20% were premenopausal, 10% were perimenopausal and 70% were menopausal. 35% were being treated with chemotherapy, 56.67% with hormonoterapy and 8.33% with anti-HER2. 78.33% had a stable partner and did not use contraception. 30% of patients were quite or very sad and depressed since starting treatment. 50% of patients believe that the treatment has worsened their body image. 75% reported that during treatment their sexual relations were not satisfactory. 61.67% believe that their sexual desire has decreased and 45% admit having more problems reaching orgasm since diagnosis.
Conclusions
Women with curable breast cancer it is important to know the impact of diagnosis and treatment on the sexual sphere. The SEXSAT-Q questionnaire is a validated scale capable of measuring the sexual satisfaction of our patients.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
M.L. Garrido Onecha.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
413P - Characteristics of patients (pts) with previously treated, oestrogen receptor-positive, HER2-negative advanced breast cancer (ER+, HER2– aBC) who had rapid progression (RP) in acelERA BC
Presenter: Miguel Martin Jimenez
Session: Poster session 03
414P - Trastuzumab deruxtecan for HER2-positive breast cancer brain metastasis: A systematic review and meta-analysis
Presenter: Isabella Michelon
Session: Poster session 03
415P - Patterns of time-to-progression intervals across clinical and liquid biopsy (LB) features in hormone receptor-positive (HR+) HER2-negative (HER2-) metastatic breast cancer (MBC) patients (pts) treated with first-line endocrine therapy (ET)
Presenter: Linda Cucciniello
Session: Poster session 03
416P - Cost-effectiveness of first-line (1L) ribociclib use vs palbociclib in the treatment of postmenopausal women with HR+/HER2− advanced breast cancer (ABC): Analysis based on final overall survival (OS) results of MONALEESA-2 (ML-2) and PALOMA-2 (PAL-2)
Presenter: Sandeep Sehdev
Session: Poster session 03
417P - New insights into second-line (2L) choices after CDK4/6 inhibitors (CDK4/6i) in hormone receptor-positive (HR+)/ human epidermal growth factor 2-negative (HER2-) metastatic breast cancer (MBC) patients (pts): Preliminary results of the HERMIONE-13 study
Presenter: Viola Cogliati
Session: Poster session 03
418P - Two-year follow-up data on the efficacy and safety of KN026, a HER2-targeted bispecific antibody combined with docetaxel as first-line treatment for HER2-positive recurrent/metastatic breast cancer
Presenter: Qingyuan Zhang
Session: Poster session 03
419P - Aspire to ASCENT: Real-world outcomes from patients with metastatic triple-negative breast cancer (mTNBC) treated with Sacituzumab govitecan (Saci) in a single academic institution
Presenter: Elaine Walsh
Session: Poster session 03
421P - Changes in cell-free DNA after short-term palbociclib and fulvestrant treatment for advanced or metastatic hormone receptor-positive and human epidermal growth factor 2-negative breast cancer
Presenter: Takayuki Iwamoto
Session: Poster session 03
422P - UK real-world data (RWD) of cyclin-dependent kinase 4/6 inhibitor (CDK4/6i) use in metastatic breast cancer (MBC)
Presenter: Georgina Gullick
Session: Poster session 03
423P - A real-world study on the clinical value of apatinib-based regimens in metastatic triple-negative breast cancer
Presenter: Huang wei
Session: Poster session 03